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Introduction 
The organism chiefly responsible for pulmonary nocardio- 
sis is Nocardia asteroides, although Nocardia caviae and 
Nocardia brasiliensis have been implicated ‘on occasion. 
Both the clinical picture and the morphologic appearance 
of the mycelium in tissue closely resemble that of actino- 
mycosis. Nocardia is seen as a primary pulmonary patho- 
gen, although it is more frequently recognized as an 
opportunistic pathogen in immunocompromised hosts or in 
patients with chronic pulmonary disease (1). 
The present case report describes a case of pulmonary 
nocardiosis due to a multiple drug-resistant strain of N. 
asteroides (MDRNA). The patient was not immuno- 
suppressed and had no history of pulmonary disorders. 
Methods 
Susceptibility testing was performed on two strains of N. 
asteroides. One strain was isolated from the patient 
reported here and the other, used as a control strain, was a 
respiratory pathogenic N. asteroides with the usual suscep- 
tibility, isolated from a 46-year-old immunocompetent male 
with right middle lobe infiltrates who had been admitted to 
Tokyo National Chest Hospital. 
CP-70,429 was provided by Pfizer, Inc (Groton, CT, 
U.S.A.). The other antimicrobial agents for susceptibility 
testing, being marketed in Japan, were obtained directly 
from the manufacturers. Compound solutions were 
prepared immediately prior to use. 
Antimicrobial susceptibility studies were performed using 
agar plates. Colonies cultured on Brain Heart Infusion agar 
(BBL) for 2 days at 37°C were inoculated with Trypticase 
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Soy Broth (Dieo) and incubated overnight at 37°C. The 
inoculum of 3 x 1 O6 colony forming units (CFU) ml - i was 
prepared using a McFarland nephelometer. The inocula- 
tion using a 0.01 ml loop with an inner diameter of 1.5 mm 
brought the final inoculum to 3 x lo4 CFU ml - ‘. The 
minimal inhibitory concentration (MIC) was determined by 
the two-fold agar dilution method using NHM Agar 
(Kyokuto Pharmaceutical Industrial Co., Ltd., Tokyo, 
Japan) with 7% defibrinated sheep blood. The MIC was 
defined as the lowest concentration of the antimicrobial 
agent that prevented visible growth after a 48-h incubation 
at 37°C. 
Case Report 
A 66-year-old male having fever, cough and sputum as chief 
complaints for 10 days was diagnosed by a family physician 
as having a common cold. However, the next day he 
suffered from shaking chills and was admitted to a hospital, 
where pneumonia was diagnosed. Although the antibiotics, 
clindamycin, clarithromycin and/or aspoxicillin, were 
administered for 11 days, his symptoms showed no 
improvement and he was referred to Tokyo Medical and 
Dental University Hospital. On admission, his body tem- 
perature was 37.8”C, no rales were heard, but his breath 
sounds were diminished in the right upper lung. Laboratory 
data on admission revealed increased acute phase reactants. 
White blood cell count was 17.4 x lo9 l- ’ (band neu- 
trophils, 3%; segmented neutrophils, 90%), C-reactive pro- 
tein (CRP) was elevated (9.6 mg dl ~ i), erythrocyte 
sedimentation rate (ESR) was increased (70 mm h- ‘), and 
LDH, GPT and AL-P were elevated (537, 63, and 
452 U l- ‘, respectively). Other haematological and bio- 
chemical data on admission were within normal ranges. 
Chest X-ray showed multiple cavitary lesions with infil- 
trates in the right upper lung field, and chest computed 
tomographic (CT) scan (Plate 1) confirmed the small cavi- 
ties. Pulmonary nocardiosis was suspected because of the 
morphological findings by X-ray, laboratory findings and 
0 1998 W. B. SAUNDERS COMPANY LTD 
874 CASE REPORTS 
PLATE 1. Chest computed tomographic (CT) scan showed 
the small cavitary lesions with infiltrates in the right 
upper lung field upon the admission to Tokyo Medical 
and Dental University Hospital. 
clinical course. Expectorated sputum was cultured, but only 
normal floral bacteria grew out. Bronchoalveolar lavage 
specimens were obtained by bronchofibrescopy for bacte- 
riological examination. From this specimen, slow-growing 
colonies with irregular creases grew on Sabouraud’s agar 
and were identified as N. asteroides by standard criteria. 
None of the following antimicrobial agents in combination 
or alone were effective: (1) minocycline [lo0 mg b.i.d., 
intravenous infusion (i.v.)] plus sulbactam-cefoperazone 
(4 g b.i.d., i.v.) plus ciprofloxacin [400 mg t.i.d., per OS 
(P.o.)]; (2) ceftazidime (2 g b.i.d., i.v.); (3) ciprofloxacin 
(400 mg t.i.d., p.0.); and (4) piperacillin (2 g b.i.d., iv.) plus 
imipenem-cilastatin (500 mg b.i.d., i.v.). 
Sulphonamides and sulphamethoxazole-trimethoprim 
were not administered because the incidence of adverse 
effects are anticipated to be higher than in the other drugs 
administered, although no allergy to sulpha drugs and 
sulphamethoxazole-trimethoprim had been reported. From 
data on MIC for the isolated N. asteroides, the authors 
determined that it was an MDRNA. Therefore, antimi- 
crobial chemotherapy was replaced with parenteral ampil- 
licin (4g b.i.d., i.v.) plus amikacin (200mg b.i.d., i.v.), 
which was effective. After defervescence and normalized 
WBC and CRP were noted, oral ampillicin (500 mg t.i.d.) 
and erythromycin (400mg t.i.d.) were administered in 
accordance with the MIC data. Complete resolution of the 
nocardial infection of the right upper lung was attained. 
Table 1 shows the MICs of antimicrobial agents tested 
against isolates of N. asteroides from this case (N. asteroides 
TMDU) and a susceptible control strain (N. asteroides 
TNCH). Nocardia asteroides TMDU demonstrated 
resistance to multiple drugs, i.e. the third-generation 
cephalosporin antibiotics (cefotaxime, cefmenoxime and 
ceftazidime), chloramphenicol, ofloxacin, ciprofloxacin, 
minocycline and doxycycline, while N. asteroides TNCH 
was susceptible to all antimicrobial agents tested. 
CP-70,429 a new penem antibiotic (2-4) developed by the 
Central Research Division, Pfizer, Inc (Groton, CT, 
U.S.A.) was active against both strains of N. asteroides, one 
of the two being an MDRNA. 
Discussion 
Nocardia asteroides most often infects humans through 
the respiratory tract, and commonly causes broncho- 
TABLE 1. Minimal inhibitory concentrations (MIC) of antimicrobial agents against clinical isolates of 
Nocardia asteroides 
MIC (ug ml- ‘) against the isolate 
Antimicrobial agent 
N. asteroides 
TMDU 
N. asteroides 
TNCH 
Ampillicin 0.20 0.10 
Cefotaxime >lOO 0.05 
Cefmenoxime >lOO 0.05 
Ceftazidime >lOO 0.20 
Chloramphenicol 6.25 0.39 
Ofloxacin >lOO 0.39 
Ciprofloxacin >I00 0.39 
Sulphamethoxazole-trimethoprim 3.13 1.56 
Rifampicin Not tested 0.025 
Erythromycin 0.05 0.025 
Roxithromycin 0.10 0.05 
Clindamycin 0.39 0.05 
Doxycycline 100 0.39 
Minocycline 50 0.39 
Kanamycin 1.56 3.13 
CP-70,429 0.78 0.10 
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pneumonia, consolidation, cavitation and pleural involve- 
ment, evident by chest X-ray. Pulmonary nocardiosis is 
usually a subacute or chronic infection with a tendency 
toward remissions and exacerbations. The present case 
showed the clinical picture of primary pulmonary nocardio- 
sis, which is most frequently observed in immunocompro- 
mised hosts, including AIDS patients. The treatment of 
pulmonary nocardiosis consists of antimicrobial agents and 
surgery. The drugs of choice for pulmonary nocardiosis are 
sulphonamides, sulphamethoxazole-trimethoprim, ampicil- 
lin, amoxicillin-clavulanic acid, minocycline, doxycycline, 
amikacin, cefuroxime, cefotaxime, ceftriaxone, imipenem, 
erythromycin and rifampicin (1,5-S). In addition, Khardori 
et al. (9) reported that newer fluoroquinolones had potent 
inhibitory and bactericidal activity against three species of 
Nocardia, including N. asteroides. 
Based on the MIC data for the isolated N. asteroides, the 
authors began treatment with parenteral ampillicin plus 
amikacin followed by oral ampicillin plus erythromycin. 
This antimicrobial chemotherapy was successful, and sur- 
gery was avoided. In this instance, in vitro data were of 
great importance in establishing treatment for nocardial 
infection. 
Nocardia asteroides TMDU is the first reported in the 
literature, to the authors’ knowledge, to have resistance to 
multiple antimicrobial agents, including the drugs of choice 
against pulmonary nocardiosis. Therefore, one should be 
aware of the possibility of such resistance and of the 
importance of testing susceptibility to antimicrobial drugs 
of every Nocardia isolate at this time. The value of accurate 
identification and complete susceptibility testing of Nocar- 
dia spp. was illustrated in a case report of pneumonia 
(10,ll). Furthermore, since the use of Auoroquinolones, 
third-generation cephalosporins and minocycline has 
increased in hospitals, in addition to increased veterinary 
antibiotic and quinolont use, the proportion of resistant 
strains to these agents may be higher than presumed. 
Nocardia asteroides is now known to contain several 
species and can be called N. asteroides complex. The suscep- 
tibility to a particular antimicrobial drug definitely differs 
among these species. For example, Nocardia farcinica is 
resistant to cefotaxime, ceftriaxone, cefamandole, ampil- 
licin, erythromycin, kanamycin, gentamicin and tobramycin 
(12,13), although Nocardia nova is susceptible to ampillicin, 
erythromycin, cefotaxime, ceftriaxone and cefamandole 
(10,12,14). However, since a method of identification that 
differentiates species comprising the N. asteroides complex 
has not yet been established, the authors recommend sus- 
ceptibility testing in a clinical setting. The determination of 
in vitro susceptibility of an isolated Nocardia spp. to various 
antimicrobial agents is an easier procedure for defining 
which drug to use for the patient with nocardiosis than the 
exact identification of the strain isolated. 
In conclusion, the case presented here indicates that 
susceptibility of every isolate of Nocardia spp. to major 
antimicrobial agents, including drugs of choice for pulmon- 
ary nocardiosis, must be tested considering the possible 
isolation of an MDRNA strain. In treating patients with N. 
asteroides infection, one should now be aware of the 
possible spread of MDRNA. 
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